The melanoma highlights from ASCO 2018 include data on the surgical management of sentinel lymph node (SLN) positive melanoma, updated results from the Checkmate 238 study evaluating adjuvant nivolumab or ipilimumab for resected stage III and IV melanoma, the overall survival (OS) data of the COLUMBUS trial assessing the combination of the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib in the treatment of unresectable BRAF-mutant melanoma and two studies evaluating immunotherapy for unresectable Merkel cell carcinoma. For a more complete overview of melanoma data presented at ASCO 2018 please refer to the official congress website (